<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13613">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02929706</url>
  </required_header>
  <id_info>
    <org_study_id>20160704</org_study_id>
    <nct_id>NCT02929706</nct_id>
  </id_info>
  <brief_title>Effectiveness of Thiopurine Dose Optimization by NUDT 15 R139C on Reducing Thiopurine-induced Leucopenia in Inflammatory Bowel Disease</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sixth Affiliated Hospital, Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sir Run Run Shaw Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sixth Affiliated Hospital, Sun Yat-sen University</source>
  <brief_summary>
    <textblock>
      NUDT15 R139C was comfirmed to be associated with thiopurine-induced leukopenia inflammatory
      bowel disease (IBD) cohort.The present study aim to explor the following questions:can
      optimizing thiopurine dose by NUDT15 genotype reduce thiopurine-induced leucopenia?What is
      the influence of this optimizing strategy on clinical outcome?Thus,we conduct a randomised
      controlled study.Subject in the conventional group detect NUDT15 genotype before thiopurine
      use and optimise dosage according to the genotype.While the subjects in the control group
      follow the conventional monitor strategy.The primary endpoint was the rate of leukopenia.The
      secondary endopoint was the efficacy of thiopurine.The follow up duration was 1 year.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single Blind (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>difference of incidence of leucopenia ADR</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Thiopurine-induced Leukopenia</condition>
  <arm_group>
    <arm_group_label>intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>test NUDT15 genotype before thiopurine use and optimize the dosage according to different genotypes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>optimize the thiopurine use by coventional strategy without konwing NUDT15 genotype</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>test NUDT15 genotype and dose optimization according to the genotype</intervention_name>
    <arm_group_label>intervention group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of IBD with indication of the use of thiopurine

        Exclusion Criteria:

          -  Contraindication of thiopurine

          -  Previous use of thiopurine

          -  co-treatment with 5-ASA or allopurinol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xiang Gao, MD,PhD</last_name>
    <phone>+86-020-38663423</phone>
    <email>hill.sea@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Sixth Affiliated Hospital, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510065</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiang Gao, MD,PhD</last_name>
      <phone>/-86-020-38663423</phone>
      <email>hill.sea@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 10, 2016</lastchanged_date>
  <firstreceived_date>October 8, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
    <mesh_term>Leukopenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
